Collectively, these findings demonstrate that dysadherin promotes HCC progression by enhancing cancer stemness and tumor aggressiveness, supporting its potential as both a therapeutic target and a prognostic biomarker. Here, FXYD5 is linked to hepatocellular carcinoma.